Skip to main content

Table 1 Patient characteristics according to the rs4950928 genotype

From: Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients

rs4950928 genotype

CC (n = 270)

CG (n = 90)

GG (n = 21)

P value

Age, years

57.6 ± 1.0

58.5 ± 1.7

55.8 ± 3.7

NS

Height, cm

158.4 ± 0.6

159.1 ± 1.0

160.4 ± 2.1

NS

Body weight, kg

59.4 ± 0.7

60.7 ± 1.2

60.8 ± 2.7

NS

Sex, n (%)

110 men (41)

41 men (46)

12 men (57)

NS

Age of onset, years

42.5 ± 1.3

44.3 ± 2.2

31.1 ± 4.5

0.032

Eosinophil count/μL

300.9 ± 17.4

359.5 ± 29.9

277.6 ± 65.1

NS

IgE level, IU/mL

412.1 ± 58.0

435.2 ± 77.9

565.4 ± 233.2

NS

GINA asthma severity, n (%)

 Mild

58 (21.5)

21 (23.3)

6 (28.6)

–

 Moderate

105 (38.9)

33 (36.7)

12 (57.1)

–

 Severe

107 (39.6)

36 (40.0)

3 (14.3)

–

Pulmonary function

 %FVC

103.3 ± 2.0

104.3 ± 3.4

103.51 ± 9.8

NS

 FEV1, L

2.3 ± 0.1

2.3 ± 0.1

2.3 ± 0.2

NS

 FEV1/FVC, %

72.9 ± 0.7

70.8 ± 1.2

70.2 ± 2.6

NS

 %FEV1

98.9 ± 1.5

98.8 ± 2.6

95.1 ± 5.3

NS

  Mild

105.8 ± 3.1

106.8 ± 5.4

91.0 ± 26.5

–

  Moderate

100.0 ± 2.3

100.5 ± 4.3

103.3 ± 22.6

–

  Severe

94.2 ± 2.3

92.5 ± 4.1

92.2 ± 33.1

–

 Equivalent FP CFC dose (μg/day)

382.1 ± 17.0

362.4 ± 29.3

228.0 ± 63.7

NS

  1. Data are expressed as the mean ± standard error
  2. GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory flow volume in one second; NS, not significant among the three groups; FP, fluticasone propionate; CFC, chlorofluorocarbon propellant